Eli Lilly Inks Covid-19 Treatment Supply Deal With U.S. Despite Drug's Recent Failure
- Oops!Something went wrong.Please try again later.
Eli Lilly inked a deal to sell up to 650,000 vials of its Covid-19 treatment candidate to the U.S., though the drug has failed a test in treating hospitalized patients. LLY stock slipped.